Pfizer Ltd.

Pfizer's historical performance shows fluctuating net sales, increasing from 681.70 Cr in 2008 to 772.27 Cr in 2009, but profitability declined, with profit after tax dropping from 299.58 Cr to 137.12 Cr due to rising expenditures. Despite sales growth, the company faced challenges in managing costs, leading to reduced profit margins.

Pfizer's historical performance has shown fluctuating net sales and profits, with net sales increasing from 681.70 Cr in 2008 to 772.27 Cr in 2009, but profit metrics, including profit before tax and earnings per share, significantly declined during the same period. Overall, while sales growth was evident, profitability decreased in later years.

The next results date for Pfizer is November 12, 2025.

As of 31-Oct, Pfizer Ltd. is facing a stock price decline to 5,215.00, down 1.64%, and has underperformed its sector and the benchmark Sensex. Despite strong fundamentals, including a high dividend yield and efficient management, investor confidence remains low, reflected in a year-to-date decrease of 0.75%.

As of 13-Oct, Pfizer Ltd. is currently priced at 5,509.00, reflecting a 3.39% increase and strong short-term performance, outperforming its sector and the Sensex. However, its year-over-year performance shows a decline of 4.03%, indicating mixed long-term prospects despite positive operational metrics.

As of 09-Oct, Pfizer Ltd. is trading at 5,260.00, up 1.43%, but has seen a significant drop in investor participation. Despite short-term gains, its long-term performance remains a concern, with a 7.98% decline over the past year.

As of September 29, 2025, Pfizer's technical trend is mildly bullish, but mixed signals from various indicators suggest caution due to conflicting MACD readings and bearish trends in Bollinger Bands and KST.

As of September 26, 2025, Pfizer's technical trend is neutral with mixed signals, showing a mildly bearish weekly MACD and Bollinger Bands, while the monthly MACD remains bullish, leading to an overall sideways outlook.

As of September 26, 2025, Pfizer's technical trend is neutral with mixed signals, as the weekly MACD is mildly bearish, the monthly MACD is bullish, and various indicators show a lack of strong conviction in either direction.

As of September 26, 2025, Pfizer's technical trend is neutral with mixed indicators, showing a mildly bearish weekly MACD and bearish Bollinger Bands, while the monthly MACD remains bullish, indicating no clear direction.

As of 24-Sep, Pfizer Ltd. is facing a stock price decline to 4,995.45, down 0.5%, with a significant drop of 11.80% over the past month. Despite a high dividend yield and strong management efficiency, its performance lags behind the Sensex, which has gained 4.58% year-to-date.

As of 23-Sep, Pfizer Ltd. is facing a stock price decline to 5,012.00, down 1.13% and on a four-day losing streak totaling a 3.65% drop. Despite strong management efficiency and a high dividend yield, the stock has underperformed significantly compared to the broader market.

As of 22-Sep, Pfizer Ltd. is facing a stock price decline to 5,070.00, down 0.78%, with a total drop of 2.53% over the last three days. Despite strong management efficiency and increased investor participation, the stock has underperformed compared to the broader market and shows negative returns over multiple periods.

As of 19-Sep, Pfizer Ltd. is facing a stock price decline to 5,110.05, down 1.22%, with a total loss of 1.76% over the last two days and 2.50% over the past week. Despite a strong dividend yield and management efficiency, the stock's performance is negatively impacted by reduced investor participation and underperformance compared to the broader market.

As of 18-Sep, Pfizer Ltd. is facing a decline in its stock price, currently at 5,173.30, down 0.54%. The stock has underperformed compared to the market, with a year-to-date decline of 1.54%, amid falling investor participation and negative sentiment.